The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4
Open accessAbstract
BRD4, a bromodomain and extraterminal domain (BET) family member, is an attractive target in multiple pathological settings, particularly cancer. While BRD4 inhibitors have shown some promise in MYC-driven malignancies such as Burkitt's lymphoma (BL), we show that BRD4 inhibitors lead to robust BRD4 protein accumulation, which may account for their limited suppression of MYC expression, modest antiproliferative activity, and lack of apoptotic induction. To address these limitations we designed ARV-825, a hetero-bifunctional PROTAC (Proteolysis Targeting Chimera) that recruits BRD4 to the E3 ubiquitin ligase cereblon, leading to fast, efficient, and prolonged degradation of BRD4 in all BL cell lines tested. Consequently, ARV-825 more effectively suppresses c-MYC levels and downstream signaling than small-molecule BRD4 inhibitors, resulting in more effective cell proliferation inhibition and apoptosis induction in BL. Our findings provide strong evidence that cereblon-based PROTACs provide a better and more efficient strategy in targeting BRD4 than traditional small-molecule inhibitors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“These results are in agreement with the unique mechanism of action of PROTACs, that usually have a longer-lasting effect and require less systemic drug exposure to be effective than their corresponding “payloads”.”
From Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity (2020) · cites this paper as [39]
In the citing paper
“This is because PROTACs act catalytically to induce protein degradation in a sub-stoichiometric manner and their effect is not limited by equilibrium occupancy32,39.”
From Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity (2020) · cites this paper as [39]
In the citing paper
“We used a less intensive dosing schedule (i.e., 41 μmol/kg, once every 3 days or q3d) for this experiment because PZ functioning as a PROTAC has a longer-acting activity than its corresponding inhibitor39 (Fig. 3b).”
From Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity (2020) · cites this paper as [39]
In the citing paper
“ARV825 is a hetero-bifunctional PROTAC (Proteolysis Targeting Chimera) that recruits BET family proteins to the E3 ubiquitin ligase CEREBLON, leading to the fast, efficient, and prolonged degradation of BET family proteins24.”
From A BET family protein degrader provokes senolysis by targeting NHEJ and autophagy in senescent cells (2020) · cites this paper as [24]
In the citing paper
“In addition, long-term dosing or high concentrations associated with BETi treatment also leads to obvious BRD4 protein accumulation and inefficient c-MYC suppression [85].”
From Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies (2020) · cites this paper as [85]
In the citing paper
“For example, PROTACs against BRD4, BTK, BCR-ABL and CDK-6 etc. have shown efficacy in leukemia [22, 44, 58, 60], whereas AR, ER, FAK, P38 PROTACs have been developed against different solid tumors [13, 49, 51, 104] (Table 1).”
From PROteolysis TArgeting Chimeras (PROTACs) as emerging anticancer therapeutics (2020) · cites this paper as [22]
In the citing paper
“PROTACs consisting of pomalidomide and OTX015 [84] or JQ1 [85] resulted in robust BRD4 degradation when used at low nanomolar concentrations [84, 85].”
From Advances in targeted degradation of endogenous proteins (2019) · cites this paper as [84]
In the citing paper
“Concomitantly, c-Myc levels were strongly depleted, and this depletion lasted longer after washout of the PROTAC than after inhibitor treatment [84].”
From Advances in targeted degradation of endogenous proteins (2019) · cites this paper as [84]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Selective inhibition of BET bromodomains
Filippakopoulos, P., Qi, J., Picaud, S., Shen, Y., Smith, W. B., Fedorov, O., Morse, E. M., Keates, T., Hickman, T. T., Felletar, I., et al. (2010) · Nature · doi:10.1038/nature09504 · Cited by 4,262
Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers
Lovén, J., Hoke, H. A., Lin, C. Y., Lau, A., Orlando, D. A., Vakoc, C. R., Bradner, J. E., Lee, T. I., & Young, R. A. (2013) · Cell · doi:10.1016/j.cell.2013.03.036 · Cited by 2,961
BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc
Delmore, J. E., Issa, G. C., Lemieux, M. E., Rahl, P. B., Shi, J., Jacobs, H. M., Kastritis, E., Gilpatrick, T., Paranal, R. M., Qi, J., et al. (2011) · Cell · doi:10.1016/j.cell.2011.08.017 · Cited by 2,888
Sakamoto, K. M., Kim, K. B., Kumagai, A., Mercurio, F., Crews, C. M., & Deshaies, R. J. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.141230798 · Cited by 2,609
Self-citationIdentification of a Primary Target of Thalidomide Teratogenicity
Ito, T., Ando, H., Suzuki, T., Ogura, T., Hotta, K., Imamura, Y., Yamaguchi, Y., & Handa, H. (2010) · Science · doi:10.1126/science.1177319 · Cited by 2,136
RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia
Zuber, J., Shi, J., Wang, E., Rappaport, A. R., Herrmann, H., Sison, E. A., Magoon, D., Qi, J., Blatt, K., Wunderlich, M., et al. (2011) · Nature · doi:10.1038/nature10334 · Cited by 1,870
The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins
Lu, G., Middleton, R. E., Sun, H., Naniong, M., Ott, C. J., Mitsiades, C. S., Wong, K.-K., Bradner, J. E., & Kaelin, W. G. (2014) · Science · doi:10.1126/science.1244917 · Cited by 1,583
Targeting MYC dependence in cancer by inhibiting BET bromodomains
Mertz, J. A., Conery, A. R., Bryant, B. M., Sandy, P., Balasubramanian, S., Mele, D. A., Bergeron, L., & Sims, R. J. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1108190108 · Cited by 1,145
Structure of the DDB1–CRBN E3 ubiquitin ligase in complex with thalidomide
Fischer, E. S., Böhm, K., Lydeard, J. R., Yang, H., Stadler, M. B., Cavadini, S., Nagel, J., Serluca, F., Acker, V., Lingaraju, G. M., et al. (2014) · Nature · doi:10.1038/nature13527 · Cited by 1,141
Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer
Asangani, I. A., Dommeti, V. L., Wang, X., Malik, R., Cieslik, M. P., Yang, R., Escara-Wilke, J. F., Wilder-Romans, K., Dhanireddy, S., Engelke, C. G., et al. (2014) · Nature · doi:10.1038/nature13229 · Cited by 941
The Mechanisms behind the Therapeutic Activity of BET Bromodomain Inhibition
Shi, J., & Vakoc, C. R. (2014) · Molecular Cell · doi:10.1016/j.molcel.2014.05.016 · Cited by 888
MYC Activation Is a Hallmark of Cancer Initiation and MaintenancePreprint
Gabay, M., Li, Y., & Felsher, D. W. (2014) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a014241 · Cited by 841
Lopez-Girona, A., Mendy, D., Ito, T., Miller, K., Gandhi, A. K., Kang, J., Karasawa, S., Carmel, G., Jackson, P., Abbasian, M., et al. (2012) · Leukemia · doi:10.1038/leu.2012.119 · Cited by 814
BET domain co-regulators in obesity, inflammation and cancer
Belkina, A. C., & Denis, G. V. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3256 · Cited by 742
Chapuy, B., McKeown, M. R., Lin, C. Y., Monti, S., Roemer, M. G. M., Qi, J., Rahl, P. B., Sun, H. H., Yeda, K. T., Doench, J. G., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.11.003 · Cited by 735
Targeting MYCN in Neuroblastoma by BET Bromodomain Inhibition
Puissant, A., Frumm, S. M., Alexe, G., Bassil, C. F., Qi, J., Chanthery, Y. H., Nekritz, E. A., Zeid, R., Gustafson, W. C., Greninger, P., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0418 · Cited by 648
Discovery of small molecule cancer drugs: Successes, challenges and opportunities
Hoelder, S., Clarke, P. A., & Workman, P. (2012) · Molecular Oncology · doi:10.1016/j.molonc.2012.02.004 · Cited by 591
Chemical Genetic Control of Protein Levels: Selective in Vivo Targeted Degradation
Schneekloth, J. S., Fonseca, F. N., Koldobskiy, M. A., Mandal, A., Deshaies, R. J., Sakamoto, K. M., & Crews, C. M. (2004) · Journal of the American Chemical Society · doi:10.1021/ja039025z · Cited by 507
Self-citationCurrent progress of siRNA/shRNA therapeutics in clinical trials
Burnett, J., Rossi, J. J., & Tiemann, K. (2011) · Biotechnology Journal · doi:10.1002/biot.201100054 · Cited by 452
French, C. A., Ramirez, C. L., Kolmakova, J., Hickman, T. T., Cameron, M. J., Thyne, M. E., Kutok, J. L., Toretsky, J. A., Tadavarthy, A. K., Kees, U. R., et al. (2007) · Oncogene · doi:10.1038/sj.onc.1210852 · Cited by 441
Development of Protacs to Target Cancer-promoting Proteins for Ubiquitination and Degradation
Sakamoto, K. M., Kim, K. B., Verma, R., Ransick, A., Stein, B., Crews, C. M., & Deshaies, R. J. (2003) · Molecular & Cellular Proteomics · doi:10.1074/mcp.t300009-mcp200 · Cited by 425
Self-citationStrategies for Discovering and Derisking Covalent, Irreversible Enzyme Inhibitors
Johnson, D. S., Weerapana, E., & Cravatt, B. F. (2010) · Future Medicinal Chemistry · doi:10.4155/fmc.10.21 · Cited by 387
Boi, M., Gaudio, E., Bonetti, P., Kwee, I., Bernasconi, E., Tarantelli, C., Rinaldi, A., Testoni, M., Cascione, L., Ponzoni, M., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1561 · Cited by 296
Efficacy of BET Bromodomain Inhibition in Kras-Mutant Non–Small Cell Lung Cancer
Shimamura, T., Chen, Z., Soucheray, M., Carretero, J., Kikuchi, E., Tchaicha, J. H., Gao, Y., Cheng, K. A., Cohoon, T. J., Qi, J., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3904 · Cited by 210
Bolden, J. E., Tasdemir, N., Dow, L. E., van Es, J. H., Wilkinson, J. E., Zhao, Z., Clevers, H. C., & Lowe, S. W. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.08.025 · Cited by 194
Ceribelli, M., Kelly, P. N., Shaffer, A. L., Wright, G. W., Xiao, W., Yang, Y., Griner, L. A. M., Guha, R., Shinn, P., Keller, J. M., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1411701111 · Cited by 187
Inhibition of BET bromodomain proteins as a therapeutic approach in prostate cancer
Wyce, A., Degenhardt, Y., Bai, Y., Le, B., Korenchuk, S., Crouthamel, M., McHugh, C. F., Vessella, R. L., Creasy, C. L., Tummino, P. J., et al. (2013) · Oncotarget · doi:10.18632/oncotarget.1572 · Cited by 184
Advances in the understanding of MYC‐induced lymphomagenesis
Klapproth, K., & Wirth, T. (2010) · British Journal of Haematology · doi:10.1111/j.1365-2141.2010.08159.x · Cited by 180
Baratta, M. G., Schinzel, A. C., Zwang, Y., Bandopadhayay, P., Bowman-Colin, C., Kutt, J., Curtis, J. D., Piao, H., Wong, L. C., Kung, A. L., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1422165112 · Cited by 171
Howell, S. J., Johnston, S. R. D., & Howell, A. (2003) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2003.08.002 · Cited by 160
Buckley, D. L., & Crews, C. M. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201307761 · Cited by 157
Self-citationBET Protein Inhibitor JQ1 Attenuates Myc-Amplified MCC Tumor Growth In Vivo
Shao, Q., Kannan, A., Lin, Z., Stack, B. C., Suen, J. Y., & Gao, L. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0305 · Cited by 86
Abstract C244: Development of the BET bromodomain inhibitor OTX015.
Noel, J. K., Iwata, K., Ooike, S., et al. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.targ-13-c244 · Cited by 82
Therapeutic Targeting of c-Myc in T-Cell Acute Lymphoblastic Leukemia (T-ALL)
Loosveld, M., Castellano, R., Gon, S., Goubard, A., Crouzet, T., Pouyet, L., Prébet, T., Vey, N., Nadel, B., Collette, Y., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.1873 · Cited by 69
Fernández, P., Scaffidi, P., Markert, E. K., Lee, J.-H., Rane, S. G., & Misteli, T. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.08.069 · Cited by 66
Chemical Inducers of Targeted Protein Degradation
Raina, K., & Crews, C. M. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.r109.078105 · Cited by 66
Self-citationChemical Approaches to Controlling Intracellular Protein Degradation
Schneekloth, J. S., & Crews, C. M. (2004) · ChemBioChem · doi:10.1002/cbic.200400274 · Cited by 34
Self-citation
Research works printed but not linked: 2
- Ge, 2007, Process for the preparation of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione compounds, US Pat. Appl.
- Sueoka, 1998, Preparation and formulation of thienotriazolodiazepine derivatives for the treatment of inflammatory intestinal diseases, venous insufficiency, and venous ulcer, PCT Int. Appl.
Cited by
Sorted by citations
Ubiquitin ligases: structure, function, and regulation
Zheng, N., & Shabek, N. (2017) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-060815-014922 · Cited by 1,499
Induced protein degradation: an emerging drug discovery paradigm
Lai, A. C., & Crews, C. M. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.211 · Cited by 1,486
Self-citationStructural basis of PROTAC cooperative recognition for selective protein degradation
Gadd, M. S., Testa, A., Lucas, X., Chan, K.-H., Chen, W., Lamont, D. J., Zengerle, M., & Ciulli, A. (2017) · Nature Chemical Biology · doi:10.1038/nchembio.2329 · Cited by 1,242
The dTAG system for immediate and target-specific protein degradation
Nabet, B., Roberts, J. M., Buckley, D. L., Paulk, J., Dastjerdi, S., Yang, A., Leggett, A. L., Erb, M. A., Lawlor, M. A., Souza, A., et al. (2018) · Nature Chemical Biology · doi:10.1038/s41589-018-0021-8 · Cited by 1,118
Proteolysis-Targeting Chimeras as Therapeutics and Tools for Biological Discovery
Burslem, G. M., & Crews, C. M. (2020) · Cell · doi:10.1016/j.cell.2019.11.031 · Cited by 1,079
Self-citation
Metadata
- Authors
- Lu, J., Qian, Y., Altieri, M., Dong, H., Wang, J., Raina, K., Hines, J., Winkler, J. D., Crew, A. P., Coleman, K., & Crews, C. M.
- Affiliations
- Arvinas (United States) (US)
- Yale University (US)
- Corresponding author
- Crews, Craig M.
- Venue
- Chemistry & Biology
- Publisher
- Elsevier BV
- Published
- 2015-06
- Volume
- 22
- Issue
- 6
- Pages
- 755-763
- ISSN
- 1074-5521 (ISSN-L)
- PMC
- PMC4475452
- OpenAlex
- W1488181101
- Cited by
- 1,140
- References
- 37
- Citations by year
- 2026: 75 · 2025: 101 · 2024: 135 · 2023: 104 · 2022: 134 · 2021: 118 · 2020: 151 · 2019: 119 · 2018: 77 · 2017: 71 · 2016: 40 · 2015: 10
- FWCI
- 29.08
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Chemistry & Biology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health
- National Institute of Allergy and Infectious Diseases (AI084140, R01AI084140)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
- Physical Sciences › Chemistry › Organic Chemistry › Chemical Synthesis and Analysis
- Keywords
- BRD4, cereblon, PROTACs, E3 ubiquitin ligase, Burkitt lymphoma, c-Myc, BET proteins, BRD4 inhibitors, protein degradation, apoptosis, cell proliferation inhibition
- MeSH terms
- Acetanilides, Bromodomain Containing Proteins, Azepines, Heterocyclic Compounds, 3-Ring, Humans, Nuclear Proteins, Peptide Hydrolases, Thalidomide, Transcription Factors, Triazoles, Signal Transduction, Proto-Oncogene Proteins c-myc, Apoptosis, Cell Cycle Proteins, Ubiquitin-Protein Ligases, Cell Line, Tumor, Adaptor Proteins, Signal Transducing, Cell Proliferation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
